Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
268 Treffer:
61.
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
62.
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Hepatobiliäre Tumoren
Datum: 2026-04-03
63.
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
64.
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-03
65.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-03
66.
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-03
67.
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-03
68.
Krebsmedikamente gezielter einsetzen: Erstes EU-Projekt integriert Pharmakogenomik in Tumorboards
Datum: 2026-03-17
69.
Cancer Registry
NCT Heidelberg » Forschung » Core Services NCT Heidelberg » Cancer Registry
Datum: 2026-03-11
70.
Tissue Bank
NCT Heidelberg » Forschung » Core Services NCT Heidelberg » Tissue Bank
Datum: 2026-03-11